Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Sep 18;19(1):205.
doi: 10.1186/s13075-017-1420-z.

Inflammasome lights up in systemic sclerosis

John Henderson  1 , Steven O'Reilly  2
Affiliations
Editorial

Inflammasome lights up in systemic sclerosis

John Henderson et al. Arthritis Res Ther. .

Abstract

Systemic sclerosis (SSc) is a pro-fibrotic condition with a poorly understood aetiology. Evidence presented by Artlett et al. in this issue suggests that the microRNA miR-155 is key, with its involvement dependent on the NLRP3 inflammasome. This links epigenetic events with inflammasome signalling in SSc and opens the door to new therapeutic strategies for the treatment of SSc.

Keywords: Caspase-1; Epigenetics; Fibrosis; Inflammasome; Interleukin-1; MCC950; Sclerosis; microRNA.

PubMed Disclaimer

Conflict of interest statement

Authors’ information

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Comment on

References

    1. Artlett CM, Sassi-Gaha S, Hope JL, Feghali-Bostwick CA, Katsikis PD. Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis. Arthritis Res Ther. 2017;19:144. doi: 10.1186/s13075-017-1331-z. - DOI - PMC - PubMed
    1. O’Reilly S. MicroRNAs in fibrosis: opportunities and challenges. Arthritis Res Ther. 2016;18:11. doi: 10.1186/s13075-016-0929-x. - DOI - PMC - PubMed
    1. Yan Q, Chen J, Li W, Bao C, Fu Q. Targeting miR-155 to treat experimental scleroderma. Sci Rep. 2016;6:20314. doi: 10.1038/srep20314. - DOI - PMC - PubMed
    1. Abtahi S, Farazmand A, Mahmoudi M, Ashraf-Ganjouei A, Javinani A, Nazari B, et al. IL-1A rs1800587, IL-1B rs1143634 and IL-1R1 rs2234650 polymorphisms in Iranian patients with systemic sclerosis. Int J Immunogenet. 2015;42(6):423–7. doi: 10.1111/iji.12212. - DOI - PubMed
    1. Coll RC, Robertson AAB, Chae JJ, et al. A small molecule inhibitor of the NLRP3 inflammasome is a potential therapeutic for inflammatory diseases. Nat Med. 2015;21(3):248–55. - PMC - PubMed